Print Page | Close Page

 
 

Genevant Sciences

Address: 887 Great Northern Way., Unit 155, Vancouver, British Columbia. V5T, CA
 
Country: Canada
 
Sectors: Proprietary Research & Manufacture, Drug Delivery, Contract Manufacturing, Contract Research & Development, Collaborations & Partnerships-Licensing, Collaborations & Partnerships-Manufacture, Collaborations & Partnerships- R&D
 
Website: https://www.genevant.com/
 
- - -
 

About Us

Genevant is a technology-focused nucleic acid delivery company with world-class platforms, the industry’s most robust and expansive lipid nanoparticle (LNP) patent estate and decades of expertise in nucleic acid drug development. We leverage our world-class delivery systems and related technologies to bring new medicines to patients who need them. We do this by selectively collaborating with leading pharma and biotech companies and fostering a culture of innovation that allows us to maintain our leadership position in the space. • Best-in-class LNP + next generation ligand conjugate technologies • First and only FDA-approved siRNA-LNP utilizes Genevant technology • Nucleic acid payload design expertise • Several hundred patents worldwide • LNP technology evaluated in more than a dozen clinical programs, representing hundreds of subjects and patients • An established leader in delivery to the liver, now focusing capabilities on other tissues and cell types • Experienced team with deep technical expertise and a track record of innovation and creative corporate partnering

 
- - -
 

Sectors

  • Proprietary Research & Manufacture
  • Drug Delivery
  • Contract Manufacturing
  • Contract Research & Development
 
  • Collaborations & Partnerships-Licensing
  • Collaborations & Partnerships-Manufacture
  • Collaborations & Partnerships- R&D
 
- - -
 

Categories

  • Biologics
  • Biotechnology
  • Drug Delivery Technology
  • Lipids
  • Liposomes
 
  • Lipid Nanoparticles (LNPs)
  • Nucleic Acids
  • Messenger RNA
  • RNA based Products
  • Vaccine Products
 
- - -
 

News

 
30th August 2023
 

Gritstone bio and Genevant Sciences Announce Option and License Agreement

 

EMERYVILLE, CALIFORNIA, VANCOUVER, BRITISH COLUMBIA, and BASEL, SWITZERLAND — August 15, 2023 (GLOBE NEWSWIRE) – Gritstone bio, Inc. (Nasdaq: GRTS),  a clinical-stage biotechnology company that aims to develop the world’s most potent vaccines, and Genevant Sciences, a leading nucleic acid delivery company with world-class platforms and a robust and expansive lipid nanoparticle (LNP) patent portfolio, today announced an agreement pursuant to which Gritstone bio, Inc. will have a multi-year option for a non-exclusive license under Genevant’s LNP technology on a pathogen-by-pathogen basis to develop and commercialize self-amplifying RNA (samRNA) vaccines.

 
- - -
 
Printed: 10-Apr-2026 at 09:23:12 hrs
Source: The Partnership Tree | https://www.pharmaservicesdirectory.com